UNSPSC 51172179: Pitofenone hydrochloride

This classification denotes an antispasmotic agent with the molecular formula C22H25NO4.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HE1ZA4ZBEX. European Medicines Agency schedules pitofenone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03880MIG. The term pitofenone hydrochloride is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule pitofenone hydrochloride under HS 29333999 and SITC 51574.

As of Q4 2014, PITOFENONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: COC(=O)C1CCCCC1C(=O)C2CCC(CC2)OCCN3CCCCC3.CL.

UNSPSC 51172179 Pitofenone hydrochloride is a Commodity code that represents a single pharmaceutical product, but recent state and local procurement activity tagged to this code reflects a broader pattern of drug testing, pharmaceutical sourcing, and prescription program management rather than procurement of pitofenone hydrochloride specifically. State and local buyers are actually sourcing drug testing services, generic pharmaceuticals through cooperative agreements, and establishing direct-to-manufacturer prescription programs. The issuing bodies include county correction departments (Collin County Community Supervision and Corrections Department), state health and human services agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local government facilities across multiple jurisdictions including Oregon). The mismatch between the code's nominal scope and the actual work being solicited suggests this code is capturing pharmaceutical-adjacent activity rather than direct procurement of pitofenone hydrochloride as an ingredient or finished product.

Recent opportunities span Texas and Minnesota. Collin County issued RFP 2026-327 on July 9, 2026, seeking offender specimen collection and drug testing services with proposals due July 23, 2026, covering immunoassay screening and confirmatory testing via LC/MS/MS or GC/MS at an estimated contract value of $600,000 over two years with three optional one-year renewals. The Texas Health and Human Services Commission posted RFI HHS0017013 on March 27, 2026, requesting vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program with a response deadline of April 3, 2026. The Minnesota Department of Administration's Office of State Procurement, administering the MMCAP cooperative, issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a March 26, 2026, response deadline, effective through June 30, 2028, for state and local facilities across participating jurisdictions. These opportunities indicate activity in pharmaceutical sourcing and testing services rather than direct procurement of this specific pharmaceutical ingredient.